During the recent session, AEON Biopharma Inc (AMEX:AEON)’s traded shares were 20.18 million, with the beta value of the company hitting 0.34. At the last check today, the stock’s price was $0.79, reflecting an intraday gain of 65.89% or $0.32. The 52-week high for the AEON share is $1236.24, that puts it down -156386.08 from that peak though still a striking 49.37% gain since the share price plummeted to a 52-week low of $0.40. The company’s market capitalization is $0.88M, and the average trade volume was 830.60K shares over the past three months.
AEON Biopharma Inc (AEON) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AEON has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
AEON Biopharma Inc (AMEX:AEON) trade information
AEON Biopharma Inc (AEON) registered a 65.89% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 65.89% in intraday trading to $0.79, hitting a weekly high. The stock’s 5-day price performance is -7.29%, and it has moved by -91.58% in 30 days. Based on these gigs, the overall price performance for the year is -99.91%.
AEON Dividends
AEON Biopharma Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AEON Biopharma Inc (AMEX:AEON)’s Major holders
Also, the Mutual Funds coming in first place with the largest holdings of AEON Biopharma Inc (AEON) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 5.76 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $3937.0 market value. The same data shows that the other fund manager holds slightly less at 4.46, or about 0.01% of the stock, which is worth about $3045.0.
